Showing posts with label pharma stocks outlook. Show all posts
Showing posts with label pharma stocks outlook. Show all posts

Pharma Stocks Outlook for the week – 15 to 18.11.2016

Pharma Stocks Outlook for the week – 15 to 18.11.2016
  www.rupeedesk.in )

Click Here  & Register To Get 2 days Trial Tips
Free Intraday Tips : Join Our Whatsapp No : 9841986753

Pharmaceutical stocks are likely to remain rangebound next week as investors will look for clues on
growth of the generic drug industry after Donald Trump won the US presidential election.
Pharmaceutical stocks may continue to feel the impact of a bearish market sentiment as the future
of Obamacare, incumbent President Barack Obama's signature health law, looks bleak. A cut in
budget allocation for the healthcare programme might hit the Indian pharmaceutical industry,
which contributes 40-50% of the generic drugs supply in the US.

Pharmaceutical stocks, which generally do not exhibit such movement, have been volatile over the
entire week as investors eyed the US presidential Elections. The stocks look neutral with downward
bias in the next week. Sun Pharma, which reported a 117% on-year rise in Jul-Sep consolidated net
profit at 22.3 bln rupees on Friday.

However, see volatility in pharmaceutical stocks as a result of an overall poor market sentiment and
earnings season. Around 40% of the generic medicine supply to the US goes from India as the
latter is a low-cost manufacturing base. Thus, any disruption in this segment will have some effect
on the industry.

Interestingly, shares of pharmaceutical companies had risen after Trump won the US presidential
election on Wednesday on some relief as his opponent Democrat Hillary Clinton's policies towards

the generic drug industry were seen as a negative for the sector.

Pharma Stocks Outlook for the week – 24 to 28.10.2016 (Earnings of heavyweights to dictate trend)

Pharma Stocks Outlook for the week – 24 to 28.10.2016
(Earnings of heavyweights to dictate trend)
  www.rupeedesk.in )

Click Here  & Register To Get 2 days Trial Tips
Free Intraday Tips : Join Our Whatsapp No : 9841986753

Earnings of Cadila Healthcare, Dr Reddy's Laboratories, GlaxoSmithKline
Pharmaceuticals and Glenmark Pharmaceuticals, scheduled for release next week, will
direct the movement in the shares of the sector. Sentiment over the sector remains
positive, so the shares may rise next week. On Wednesday, Cadila Healthcare is
expected to report a consolidated net profit of 3.93 bln rupees and a topline of 24.97 bln
rupees.

We expect the company's consolidated net sales to grow by nearly 9% to 25.5 bln
rupees driven by a rise in revenue from its US business. Growth in the US formulations
business (of Cadila) is expected to be largely driven by launch of authorized generic of
Asacol HD.

For the next week, the stock is expected to be neutral, and will find support at 382
rupees. But on a longer term, the bias remains positive, and it could rebound towards
399 rupees. On Tuesday, Dr Reddy's is expected to report a consolidated net profit of
3.13 bln rupees, while it is expected to report a topline of 34.76 bln rupees. We expect
the stock to rise towards 3,185 rupees, above which it could test 3,227 rupees. The
stock is finding strong support on a long term basis at 3,012 rupees.
India's largest pharmaceutical company Sun Pharmaceutical Industries is expected to
find strong support in the range of 710-735 rupees. While the bias is likely to be neutral,
if it stays above 735 rupees, it could rise towards 759 rupees, and above it test 772
rupees.

Pharma Stocks Outlook for the week – 17 to 21.10.2016

Pharma Stocks Outlook for the week – 17 to 21.10.2016
  www.rupeedesk.in )

Click Here  & Register To Get 2 days Trial Tips
Free Intraday Tips : Join Our Whatsapp No : 9841986753

Earnings of pharmaceutical companies for the September quarter will be the major trigger
for the sector going forward. As such, the stocks of these companies might be subdued next
week, as investors maintain caution. The Nifty Pharma index is likely to trade with a negative
bias in the range of 11300-11550 points next week.

Among companies, Biocon and its subsidiary Syngene International will report their earnings
on Thursday. Biocon is expected to report a consolidated net profit of 1.52 bln Rupees for
Jul-Sep. The positive outlook on Biocon due to the recent approval for insulin glargine in
Japan, as well as positive news pertaining to its insulin manufacturing facility in Malaysia.
So many speculative investors are expect regulatory issues to weigh on the earnings of
pharmaceutical companies for the September quarter. Among the factors that may be
tracked in the companies' earnings would be the impact of a ban on over 300 fixed-dose
combinations of drugs, as well as price controls in the case of essential medicines.

Pharma Stocks Outlook for the week – 03 to 07.10.2016 May rebound next week; Aurobino Pharma top pick

Pharma Stocks Outlook for the week – 03 to 07.10.2016
May rebound next week; Aurobino Pharma top pick
  www.rupeedesk.in )

Click Here  & Register To Get 2 days Trial Tips
Free Intraday Tips : Join Our Whatsapp No : 9841986753

Despite challenges over the short term on both domestic and international fronts, stocks of most
pharmaceutical companies are likely to rebound next week as investors continue to be bullish over
the sector's long-term prospects. Favourable valuation of large-caps following a near 10% decline in
the Nifty Pharma index in the last one year on regulatory issues is another reason aiding investor
sentiment. Aurobindo Pharma is the preferred pick of most dealers due to expectation of strong
earnings from the company, which has one of the largest pipeline of generic drugs that are awaiting
US Food and Drug Administration's approval. For the next week, the Hyderabad-based company's
stock is expected to rise further. It would be a lifetime high for a stock that was hovering around just
100 rupees three years ago. The stock trades at a 30% discount to the pharmaceutical sector. We
expect the current 30% discount to narrow as the company delivers strong growth and reducing
debt.

The largest company in the sector Sun Pharmaceutical Industries is expected to rebound from this
week's losses. Resolution of its regulatory issues surrounding its plant at Halol is a key trigger for the
stock. The US Food and Drug Administration had issued a warning letter to the plant for noncompliance with good manufacturing practices. The analyst remains uncertain about when most
pharmaceutical companies' regulatory issues will be resolved. Yesterday, Cipla declined 4% after
company said the US Food and Drug Administration issued a Form 483 with four observations related to deviation from good manufacturing practices across three units at its Goa facility. Cipla was the worst hit in the sector this week, and is likely to correct further next week.

Next week, the broad market will also be in focus as market participants focus next week on account
of Reserve Bank of India's monetary policy. Investors will also monitor government officials and

ministers' comments given the on going geopolitical tensions between India and Pakistan.

Pharma Stocks Outlook for the week – 19 to 23.09.2016 Positive; valuations of large-caps favourable

Pharma Stocks Outlook for the week – 19 to 23.09.2016
Positive; valuations of large-caps favourable

Stocks of pharmaceutical companies are likely to trade with a positive bias next week with buying
interest being supported by favourable valuations, particularly those of large-caps. Improvement in
sales of domestic pharmaceutical products in July is also seen keeping sentiment upbeat. According
to data from market research firm AIOCD-AWACS, the domestic pharmaceutical market grew by
14.7% on year in July as against a growth of 9.7% in June, led by robust sales of anti-infective and
respiratory drugs. Stocks of large-cap companies like Sun Pharmaceutical Industries, Dr Reddy's
Laboratories, and Lupin have been under pressure due to regulatory issues at their manufacturing
units and price erosion in products in the US. However, looking at their current valuations, upside
momentum is expected in the medium term.

Moreover, these companies have taken sufficient remedial measures at their plants and hence the
regulatory issues are likely to be resolved sooner rather than later. Aurobindo Pharma is receiving
support from a strong product pipeline for the US market and by good pace of product approvals. On
technical charts, the trend for Sun Pharmaceutical, Dr Reddy's, Lupin, and Aurobindo Pharma is seen
positive. Cipla, which has gained significantly over the last one month, may see some consolidation in the near term. The technical analyst is also positive on Glenmark Pharmaceuticals and Divi's
Laboratories in the near-to-medium term.

Pharma Stocks Outlook for the week – 06 to 09.09.2016 Mixed; broader market trend to lend cues

Pharma Stocks Outlook for the week – 06 to 09.09.2016
Mixed; broader market trend to lend cues

Stock-specific movement is likely in pharmaceutical companies next week amid lack of fresh triggers. Trend in broader market will lend some cues to the sector. Benchmark indices are seen positive next week because sentiment remains buoyant after announcement of new policy initiatives for the construction sector and robust sales numbers reported by most automobile companies in August. While the broader market is seen positive, the gains in pharma space are expected to be limited compared to other sectors like infrastructure and banking. Stocks of Cipla, which hit a six-month high of 587.50 rupees on Aug 31, may consolidate next week after the recent rally but a sharp correction is unlikely. The bias for Cipla remains firm on optimism that the company's business restructuring plans will propel future growth.

Stocks of Sun Pharmaceutical Industries have rebounded 4% during the week. Among mid-caps,
stocks of Ajanta Pharma, which have surged more than 20% in the last one month, are likely to
continue the upward movement as analysts are positive about its long-term fundamentals. However,
some bouts of profit booking cannot be ruled out in the near term. We are positive about Ajanta
based on its continuing outperformance in domestic formulations and healthy ANDA (abbreviated
new drug applications) pipeline (in the US). To factor in the faster ANDA approvals, strong execution and better returns.

Pharma Stocks Outlook for the week – 25 to 29.07.2016 (Apr-Jun results to set trend; Dr Reddy's eyed)

Pharma Stocks Outlook for the week – 25 to 29.07.2016
(Apr-Jun results to set trend; Dr Reddy's eyed)
  www.rupeedesk.in )

Stock-specific movement is expected in the pharmaceutical sector next week with market participants
keeping a close watch on Apr-Jun earnings of companies. A number of pharma companies will detail
their financial results next week. Focus will be on shares of Dr Reddy's Laboratories, which is
scheduled to release its earnings on Tuesday.

Other companies in the sector that will detail earnings next week are Unichem Laboratories, Ajanta
Pharma, Bliss GVS Pharma, Torrent Pharmaceuticals, GlaxoSmithKline Pharmaceuticals, Indoco
Remedies, Sun Pharma Advanced Research Co, and Alembic Pharma.

While earnings will drive the trend in pharma stocks, the overall bias is seen positive due to easing of
regulatory concerns and improved pace of product approvals in the US, the main market for most
pharma companies. This week, Sun Pharmaceutical Industries, Glenmark Pharmaceuticals, and
Aurobindo Pharma got approval from the US Food and Drug Administration for their generic of
cholesterol drug Crestor. Overseas players like Mylan and Teva Pharmaceutical Industries also got
approval for generic of Crestor.

With so many companies receiving approvals for Crestor generic, at least six-eight generics are
expected during the exclusivity period in the US, though only few companies could compete with high volume.

Pharma Stocks Outlook for the week – 18 to 22.07.2016 (Seen trading range-bound next week, as corporate earnings)

Pharma Stocks Outlook for the week – 18 to 22.07.2016
(Seen trading range-bound next week, as corporate earnings)

Stocks of pharmaceutical companies are seen trading range-bound next week, as investors await
corporate earnings for Apr-Jun to provide fresh cues. Biocon and its listed-subsidiary Syngene
International will announce their Apr-Jun earnings on Thursday, while Sanofi India will detail its
earnings on Jul 22.

Stock of Biocon are in the overbought zone, some correction is expected ahead of the announcement
of the earnings. Overall, in the pharmaceuticals space may see some consolidation, following gains in
past month due to the recent news that manufacturing plants of a number of pharma companies have
been cleared by the US Food and Drug Administration.

In the last two or three months, there was a marked increase in the receipt of Establishment Inspection Reports from the US FDA. Such receipts indicate that a facility is in compliance with standards required by the US FDA. Most large-cap pharmaceutical are expected to trade range-bound next week.

Pharma Stocks Outlook for the week – 11 to 15.07.2016

Pharma Stocks Outlook for the week – 11 to 15.07.2016
(Positive Bias as regulatory concerns ease)

Stocks of pharmaceutical companies may continue to trade with a positive bias next week due to
easing regulatory concerns, but some profit booking at higher levels is likely following the recent
gains. The Nifty pharma index has surged 8.5% in two weeks.

The recently has announced of news that manufacturing plants of a number of pharma companies have been cleared by the US Food and Drug Administration has given some optimism.

Cadila Healthcare's Moraiya facility in Gujarat, which was issued a warning letter in December, has
received an Establishment Inspection Report from the US FDA, indicating the closure of the inspection carried out by the regulator during Aug 28-Sep 5, 2014. The company, however, said that
this establishment report does not indicate complete resolution of issues highlighted in the warning
letter.

Stocks of Cadila Health rose nearly 10% this week. Lupin share could see some correction after rising nearly 6% this week as its Dabhasa unit has received Form 483 from the US FDA with two
observations.

However, the downside is seen limited and overall outlook remains positive for Lupin as its Goa unit
has received an Establishment Inspection Report from the US FDA for the inspection carried out in
July 2015. However, the regulator is still reviewing the responses sent by the company on the
observations made during the inspection in March. The regulator issues an establishment inspection
report upon successful completion of a site inspection.

The easing of regulatory issues has lifted sentiment but some correction is likely ahead of the Apr-Jun
earnings, which will be declared in coming weeks.

Pharma Stocks Outlook for the week -04 to 08.07.2016 (Positive next week; Dr Reddy's may gain more)

Pharma Stocks Outlook for the week -04 to 08.07.2016
(Positive next week; Dr Reddy's may gain more)

The positive momentum in stocks of pharmaceutical companies may continue next week due to
improved sentiment as no fresh regulatory issues have surfaced in past few weeks. In fact, a number of companies have come out with statements that the US Food and Drug Administration has not made any critical observations relating to non-compliance of good manufacturing practices at their plants in the recent inspections. On technical charts, too, the trend looks firm for pharma companies. Last week's gains in (Nifty 50) pharma index are a good sign. It could rise to 11350-11380 zones, and if it breaks above these levels on the higher side, then we can see some 6-8% more upside. The sector has been reeling under stress for over a year as regulatory issues at manufacturing units of many companies have affected earnings. However, there is a hope that things will start improving now.

If you see, these days most companies are saying that no Form 483s have been issued to their plants in recent inspections by US FDA. Companies like Dr Reddy's and Sun Pharma have said they have taken remediation measures and will invite US FDA for re-inspection. This has improved the sentiment. Sun Pharmaceutical Industries had said earlier that it will request the US FDA to re-inspect its Halol unit, which got warning letter in December, by June-end.

In May, Lupin said the US FDA had cleared its Mandideep and Aurangabad units. On Thursday, Strides Shasun said its Bengaluru unit had cleared US FDA inspection. Alembic Pharmaceuticals also said on Thursday that its Panelav unit has cleared US FDA inspection. JB Chemicals and Pharmaceuticals said earlier this week that US FDA had cleared its Panoli unit.

Among midcaps, Alembic Pharma, Glenmark Pharmaceuticals, and Bliss GVS Pharma are seen
trending on a stronger note. Glenmark could see 8-10% rise in the next couple of weeks. In pharma, would advise buying on dips. Select large-caps will rise but mostly the upside will be driven by
midcaps.

Pharma Stocks Outlook for the week – 27.06.2016 to 01.07.2016, Seen weak next week as Europe exposure to weigh

Pharma Stocks Outlook for the week – 27.06.2016 to 01.07.2016, Seen weak next week as Europe exposure to weigh

Stocks of pharmaceutical companies are likely to trade with a negative bias next week as investors
tackle the uncertainty caused by UK's decision to exit the European Union and its impact on some
firms which have considerable exposure to the region. Volatility is also expected as traders roll over
positions to July derivatives contracts ahead of the expiry of June series on Thursday. Volatility in the
euro and pound sterling following UK's decision to leave the Union is seen causing considerable
impact on some pharmaceutical companies' going forward.

Total sales in the EU, including UK, account for 22% of sales of Aurobindo Pharma, about 27% of
sales of Ipca Laboratories, 13% of sales of Torrent Pharmaceuticals, 9% of sales of Glenmark
Pharmaceuticals and 5% of sales of Dr Reddy's Laboratories. Wockhardt has a manufacturing facility
in the UK, and the country contributes a third of its revenue. While we expect the broader market to
recover next week, with some volatility induced by foreign investors selling on rise, the risk-averse
approach following the UK referendum is seen weighing on pharmaceutical stocks, which is still seen
reeling under regulatory issues concerning some companies.

Banks and automobile we are positive about, but we are still uncertain about pharmaceutical stocks
as many have regulatory issues. Many pharmaceutical companies are troubled by global regulators,
particularly the US Food and Drug Administration, over violation of quality norms at their
manufacturing plants. This has hurt earnings of all these companies, which is weighing on investor
sentiment.

Most large-cap pharmaceutical stocks are likely to trade with a negative bias or are seen range
bound. The only stock the analyst is positive about in the sector is the mid-cap Divi's Laboratories.
The analyst expects the scrip to gain 5-6% from yesterday's closing price of 1,100 rupees. This week,
the stock declined 1.2%. Over the medium term, the stock is expected to remain weak. Glenmark
Pharmaceuticals is also expected to remain weak in the medium-to-long term.

Pharma Stocks Outlook for the Week – 20 to 24.06.2016 Sideways; bias seen weak on regulatory woes

Pharma Stocks Outlook for the Week – 20 to 24.06.2016
Sideways; bias seen weak on regulatory woes

Stocks of pharmaceutical companies are seen trading range bound with a negative bias next week due to persisting regulatory issues. While the overall trend for pharma sector remains weak, movement in stocks is likely to be largely range bound next week on caution ahead of the referendum on Thursday to decide whether the UK will continue to be a part of the European Union or not. Pharma stocks may gain in line with broader market if the UK decides to stay in the EU but the upside potential is seen limited. Since November, we are seeing pressure on pharma and the weakness is likely to continue. There are no signs of a possible recovery on charts. Aurobindo Pharma and Sun Pharmaceutical Industries look weak. Lupin and Cadila Healthcare are expected to remain under pressure but Dr Reddy's Laboratories could see some rebound. Many companies in the sector are facing troubles with global regulators, particularly the US Food and Drug Administration, due to violation of quality norms at their manufacturing plants. This has hurt earnings of all such companies, which is weighing on investor sentiment. Domestic sales of pharma companies have also taken some hit due to government's ban on 344 fixed-dose combination drugs and
increased number of products under the National List of Essential Medicines.

Pharma companies are grappling with a number of issues such as pricing pressure on generic drugs in the US, delays in product approvals, currency headwinds in emerging markets and regulatory scrutiny. According to a joint study by the Associated Chambers of Commerce and Industry of India and TechSci Research, India's pharmaceutical products' exports may see a compounded annual growth of just 8% during 2015-20, compared with a CAGR of around 15% in 2010-14 due to lower exports in the US, the largest market for Indian pharma companies.

Pharma Stocks Outlook for the week – 13 to 17.06.2016 (Seen falling next week; Cipla may buck trend)

Pharma Stocks Outlook for the week – 13 to 17.06.2016
(Seen falling next week; Cipla may buck trend)

Pharmaceutical stocks are expected to be subdued next week as investors continue to remain bearish on the sector on account of regulatory issues surrounding the companies and their weak earnings for the March quarter. In the recent past, the regulatory activism (US FDA's stringent inspections and actions) has created some uncertainties surrounding Indian pharma companies and could mar their financial performance in the near term.

Despite the regulatory issues putting companies' earnings under pressure, our view is positive on the long-term growth prospects of the sector. Market participants would prefer to invest in other sectors that look fundamentally sound than pharmaceutical over the short term.

Over the next week, all pharmaceutical stocks, except Cipla, are likely to fall. The broader market will also lend cues to the sector's stocks next week, especially as investors await the consumer price-index based inflation data for May, due on Monday, and US Federal Reserve's decision on monetary policy, due late on Wednesday.

Pharma Stocks Outlook for the week – 06 to 10.2016 (Seen subdued next week; Sun Pharma may rebound)

Pharma Stocks Outlook for the week – 06 to 10.2016
(Seen subdued next week; Sun Pharma may rebound)

Shares of most pharmaceutical companies are likely to be subdued in the coming week,  continuing the trend seen in the last few sessions on account of their disappointing Jan-Mar results. Overall, the quarter saw a 360 bps EBITDA margin miss on rising  R&D (research and development) costs, price erosion in the US, and EM (emerging markets)
currency headwinds.

With no respite seen on any of these fronts, FY17 is unlikely to be any better. Among stocks, Glenmark Pharmaceutical, this was the worst hit after Sun Pharmaceutical Industries this week.

Sun Pharmaceutical Industries, though, is showing signs of recovery and may rise towards 762 rupees. The stock witnessed a sharp decline this week on account of its weak 8-10% guidance for 2016-17 (Apr-Mar). The management also said remedial work at Halol unit is progressing well and the company plans to send a request to the US Food and Drug Administration to re-inspect the plant by June-end.

Remedial measures are a key factor for pharmaceutical companies over the medium term as most of them are facing regulatory issues. Resolution of USFDA issues (including Form 483s) would provide clarity and result in new product approvals which have been getting delayed.

Pharma Stocks Outlook for the week – 23 to 27.05.2016 (Mixed; weak rupee to aid, Cipla result eyed)

Pharma Stocks Outlook for the week – 23 to 27.05.2016
(Mixed; weak rupee to aid, Cipla result eyed)

Stocks of Pharmaceutical companies are seen trading mixed next week with Jan-Mar earnings providing fresh triggers and a weak rupee against the dollar lending some support. On Friday, the rupee ended at 67.44 per dollar--its lowest closing level since Mar 2. As exports form a major chunk of sales of most Pharmaceutical companies, the fall in the rupee against the greenback is seen as a positive. Weak sentiment in the broad market and regulatory issues faced by a number of Pharmaceutical companies will, however, continue to put pressure on the stocks.

Volatility in the market is expected next week due to the expiry of the May derivatives contracts on Thursday. Market participants will keep an eye on Jan-Mar earnings of Nifty 50 constituent Cipla, which are due on Tuesday. Cipla's consolidated net profit is seen rising 44.8% on year to 3.76 bln rupees in Jan-Mar, and net sales are seen up 13.9% at 33.96 bln rupees. The company's net profit should grow due to margin improvement, reduction in interest cost, higher other income, and lower tax rate.

Stocks of Cipla could see a rebound next week as they are in an oversold zone. Torrent Pharmaceuticals, Jubilant Life Sciences, AstraZeneca Pharma India, GlaxoSmithKline Pharmaceuticals, Natco Pharma, and Indoco Remedies are other key companies scheduled to release Jan-Mar earnings next week. Stocks of Lupin, which fell to a one-month low despite strong Jan-Mar results, are likely to consolidate next week but the bias remains largely negative. Concerns over regulatory issues at the company's Goa unit, a likely rise in costs due to integration of Gavis Pharmaceuticals, and limited visibility on meaningful products pipeline for the US may weigh on Lupin's stock.

Pharma Stocks Outlook for the week – 09 to 13.05.2016 Mixed next week; earnings to be in focus

Pharma Stocks Outlook for the week – 09 to 13.05.2016
Mixed next week; earnings to be in focus

Pharmaceutical stocks are seen mixed next week, with Jan-Mar earnings of Cadila Healthcare, Dr
Reddy's Laboratories and Glenmark Pharmaceuticals key triggers for their scrips. Cadila Healthcare is
seen reporting a consolidated net profit of 3.79 bln rupees, up 8.3% on year. Dr Reddy's Laboratories is expected to report a 6.6% growth in its Jan-Mar consolidated net profit to 5.5 bln rupees. Increased competition in Valcyte generic and a likely write-off in its Venezuela earnings could weigh on result.

Wockhardt is likely to be in focus on Monday, after reporting 26% rise in its Jan-Mar consolidated net profit to 429 mln rupees. Pfizer may extend gains after reporting a 57% surge in its Jan-Mar net
profit to 669.7 mln rupees on account of lower tax outgo and rise in other income. Yesterday, the
stock ended up 2%. Market participants remain upbeat on Cipla and Aurobindo Pharma as the
companies are seen reporting strong earnings. Aurobindo Pharma is on top of the radar of many
analysts, due to the company's strong drug pipeline. Considers the stock as its top pick as it filed the
maximum number of drug master files in 2015-16 (Apr-Mar) at 12.

Pharma Stocks Outlook for the week – 02 to 06.05.2016 Mixed; Lupin may gain, Wockhardt result eyed

Pharma Stocks Outlook for the week – 02 to 06.05.2016
Mixed; Lupin may gain, Wockhardt result eyed

Stocks of pharmaceutical companies are seen trading mixed next week, with Lupin Ltd likely to
extend gains on expectation of strong Jan-Mar earnings and optimism due to recent product launches in the US. On Thursday, Lupin said it has reintroduced Methergine oral tablets in 0.2 mg strength in the US, which will bolster its branded drug portfolio. Methergine is the only US Food and Drug Administration-approved oral uterotonic and is a preferred oral agent in the prevention and
management of postpartum haemorrhage. This week, shares of Lupin rose 3%. Stocks of Aurobindo
Pharma Ltd are expected to trade range bound in the coming days after a 2.5% fall this week.

While sporadic upside movements may be triggered by any new product approvals in the US, gains
are likely to be limited. Market participants will await Jan-Mar earnings of Wockhardt Ltd, Pfizer Ltd,
Sun Pharma Advanced Research Co Ltd, and Aarti Drugs Ltd next week. We expects Wockhardt to
post a consolidated net profit of 380 mln rupees in Jan-Mar, up 11.5% from a year ago, and net sales of 11.33 bln rupees, up 5.0% on year. Pfizer's net profit in Jan-Mar is seen at 593 mln rupees, up 38.9% on year, and net sales are expected to rise 11.9% to 5.10 bln rupees. The pharmaceutical
pack has been in a downward correction phase in the past two months due to regulatory headwinds,
but within the sector, Sun Pharmaceutical Industries Ltd is favourably placed and looks attractive at
current levels.

We believe that the stock's risk-reward ratio is decent and gives medium-term investors an opportunity to buy. It expects a 15% upside in the stock in six months. We believe the stock is
poised to resume its medium-term uptrend after concluding a healthy corrective phase.

Pharma Stocks Outlook for the week – 25 to 29.04.2016 (Stock-specific movement likely; earnings eyed)

Pharma Stocks Outlook for the week – 25 to 29.04.2016
(Stock-specific movement likely; earnings eyed)

Stock-specific movement is likely in the pharmaceutical space in the coming week with
investors keeping an eye on earnings for the Jan-Mar quarter. Biocon and its listed arm,
Syngene International, will release earnings on Tuesday, Alembic Pharmaceuticals on
Wednesday, Granules India on Thursday and Ajanta Pharma and Sanofi India on Apr
29.

Bengaluru based Biocon's consolidated net profit is seen down 45.3% on year at 1.10
bln rupees and net sales up 6.2% at 8.81 bln rupees during Jan-Mar. Alembic's Pharma's
consolidated net profit is likely to rise 133.1% on year to 1.64 bln rupees and net sales
may increase 55.8% to 7.82 bln rupees.

Glenmark Pharmaceuticals, which rose 4% this week, may continue see some
consolidation next week. Easing concerns over regulatory issues at Glenmark's Indore
plant are likely to provide support to the stock.

The three observations made by the US Food and Drug Administration on Glenmark's
Indore unit are benign and not related to data integrity. The fact that Glenmark has
received two product approvals in the US from the Indore plant post FDA observations
also eases concerns over any holdback of approvals by the regulator.

Pharma Stocks Outlook for the week – 18 to 22.04.2016

Pharma Stocks Outlook for the week – 18 to 22.04.2016

Pharmaceutical stocks are seen underperforming the broader arket next week on account of regulatory concerns and as investors focus on nfrastructure sector and those dependent on rural demand. The bias for the broad market remains positive after benchmark indices ended at their highest levels since Jan 1.

On technical charts, most stocks are approaching their 100-day moving average, and are
seen correcting after they hit their resistance.

Investors would also be aligning their portfolio to expectations of earnings for the quarter ended March, which will be released by companies over the next one-and-a-half month. Individual earnings are expected to be mixed, with players like Sun Pharma, Lupin, Aurobindo Pharma, Torrent and Natco likely to report good growth, while Dr Reddy's, Cadila and Glenmark would disappoint.

Investors will eye Delhi High Court's hearing on the government's ban on 344 fixed dose combination of drugs on Monday. Stocks affected by the ban--Pfizer, Abbott India, Glenmark Pharmaceuticals, Procter & Gamble Health and Hygiene Care—would be in focus.

Traders remain cautious on the stocks on account of the uncertainty due to the hearing
and would be hoping for clarity on the matter, according to market participants.

Pharma Stocks Outlook for the week – 11 to 15.04.2016 (Rangebound; earnings to provide fresh cues)

Pharma Stocks Outlook for the week – 11 to 15.04.2016
(Rangebound; earnings to provide fresh cues)

Shares of pharmaceutical companies may trade in a narrow range next week as investors await fresh cues from Jan-Mar and 2015-16 (Apr-Mar) earnings that will be released by companies over the next one-and-a-half month.

The bias remains weak due to ongoing regulatory issues in a number of pharma companies. However, we expect Jan-Mar earnings to be better than the previous quarters for most companies, which is a positive.

Shares of Lupin and Aurobindo Pharma are likely to gain more, while Sun Pharmaceutical Industries' shares are seen trading in a range. Shares of Ipca Laboratories that fell to a 52-week low on account of aggravating regulatory woes are expected to be under pressure. The Global Fund, which sources Ipca Lab's anti-malaria drugs for  African markets, has decided not buy the company's products due to pending regulatory issues at its manufacturing units.

The company's units at Ratlam, Indore Special Economic Zone, and Silvassa are under
import alert of the US FDA on account of violations of good manufacturing practices.
Lupin's stock, which on Mar 29 fell to its lowest level since August 2014 due to the US
Food and Drug Administration's observations on its manufacturing units, has been
recovering and is likely to continue its upward movement in the near term.